Physician profile
Gerald A Levine
NPI 1508886144
$63,507.81
in general payments reported to CMS, 2019-2025
24 companies · $788 in 2025
The $788 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $45K · 2020: $6,182 · 2021: $5,803 · 2022: $1,984 · 2023: $2,762 · 2024: $928 · 2025: $788.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,318 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,100 · Gift: $59.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,318.27 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,100.00 |
| Gift | $59.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $58,343.02 | 2019-2025 | |
| Lilly USA, LLC | $996.90 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Clarus Therapeutics INC. | $750.00 | 2020 | |
| Novo Nordisk INC | $587.28 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $437.45 | 2019-2022 | |
| Abbott Laboratories | $426.75 | 2019-2024 | Freestyle Libre 3 |
| Ascendis Pharma Endocrinology INC | $338.56 | 2024-2025 | Yorvipath |
| Boehringer Ingelheim Pharmaceuticals, INC. | $338.44 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Mannkind Corporation | $233.83 | 2020-2024 | Afrezza |
| Ibsa Pharma INC. | $191.81 | 2019-2025 | Flector, Tirosint, Licart |
| Bayer Healthcare Pharmaceuticals INC. | $133.01 | 2021-2023 | |
| Antares Pharma, INC. | $127.91 | 2019-2023 | Nocdurna, Tlando, Xyosted |
| Sanofi-Aventis U.S. LLC | $123.29 | 2019-2022 | |
| Vistapharm, INC. | $99.58 | 2021 | |
| Dexcom, INC. | $79.02 | 2021-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar, INC. | $62.22 | 2023 | |
| Amgen INC. | $54.27 | 2023-2024 | Evenity, Prolia |
| Merck Sharp & Dohme LLC | $36.18 | 2020 | |
| Corcept Therapeutics | $34.50 | 2025 | Korlym |
| Janssen Pharmaceuticals, INC | $28.30 | 2019 | |
| Medtronic, INC. | $24.37 | 2022 | |
| Halozyme INC | $23.52 | 2023 | |
| Novartis Pharmaceuticals Corporation | $20.74 | 2021 | |
| Gilead Sciences, INC. | $16.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Levine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.